臨床整形外科58巻3号

2023年03月発行

特集 二次骨折予防に向けた治療管理

二次骨折予防のための薬物療法

著者： 井上玲子¹ 井上大輔¹

所属機関： ¹帝京大学ちば総合医療センター第三内科

ページ範囲：P.273 - P.280

既存骨折は低骨密度や年齢とともに重要な骨折リスクである．二次骨折の大部分が初回骨折後の早期に生じることから，その予防のためには骨折後早期の骨折の危険性が非常に高まった状態において適切な治療薬を選択し，その後も半永続的に継続することが求められる．骨折リスクの非常に高い状態では骨形成促進薬の積極的な使用により骨密度を速やかに回復させ，直近の骨折リスクを早急に低下させることが優先される．また，骨吸収抑制薬による治療継続と骨折リスクの再評価も重要である．

参考文献

1) Toth E, Banefelt J, Åkesson K, et al. History of previous fracture and imminent fracture risk in Swedish women aged 55 to 90 years presenting with a fragility fracture. J Bone Miner Res 2020;35(5):861-8.

2) Schrøder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. Clin Orthop Relat Res 1993;(289):166-9.

3) Hadji P, Schweikert B, Kloppmann E, et al. Osteoporotic fractures and subsequent fractures:imminent fracture risk from an analysis of German real-world claims data. Arch Gynecol Obstet 2021;304(3):703-12.

4) van Geel TA, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 2009;68(1):99-102.

5) Conley RB, Adib G, Adler RA, et al. Secondary fracture prevention:consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res 2020;35(1):36-52.

6) Bouxsein ML, Eastell R, Lui LY, et al. Change in bone density and reduction in fracture risk:a meta-regression of published trials. J Bone Miner Res 2019;34(4):632-42.

7) Cummings SR, Cosman F, Lewiecki EM, et al. Goal-directed treatment for osteoporosis:a progress report from the ASBMR-NOF Working Group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017;32(1):3-10.

8) Curtis EM, Reginster JY, Al-Daghri N, et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res 2022;34(4):695-714.

9) Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. New Engl J Med 2007;357(18):1799-809.

10) Saito T, Sterbenz JM, Malay S, et al. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures:systematic review and meta-analysis. Osteoporos Int 2017;28(12):3289-300.

11) Jin YZ, Lee JH, Xu B, et al. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events:a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 2019;20(1):399. doi:10.1186/s1289-019-2769-8.

12) Shi L, Min N, Wang F, et al. Bisphosphonates for secondary prevention of osteoporotic fractures:a bayesian network meta-analysis of randomized controlled trials. Biomed Res Int 2019;2019:2594149. doi:10.1155/2019/2594149.

13) Wen F, Du H, Ding L, et al. Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women:network meta-analysis followed by factor and cluster analysis. PLoS One 2020;15(6):e0234123. doi:10.1371/journal.pone.0234123.

14) Boonen S, Adachi J D, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011 Jun;96(6):1727-36. doi:10.1210/jc.2010-2784.

15) Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344(19):1434-41.

16) Beall DP, Feldman RG, Gordon ML, et al. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study. Osteoporos Int 2016;27(3):1191-8.

17) Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women:a network meta-analysis. J Clin Endocrinol Metab 2019;104(5):1623-30.

18) Silverman S, Langdahl BL, Fujiwara S, et al. Reduction of hip and other fractures in patients receiving teriparatide in real-world clinical practice:integrated analysis of four prospective observational studies. Calcif Tissue Int 2019;104(2):193-200.

19) Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study):extension of a randomised controlled trial. Lancet 2015;386(9999):1147-55.

20) Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93(3):852-60.

21) Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis:a randomized clinical trial. JAMA 2016;316(7):722-33.

22) Leder BZ, Zapalowski C, Hu MY, et al. Fracture and bone mineral density response by baseline risk in patients treated with abaloparatide followed by alendronate:results from the phase 3 ACTIVExtend trial. J Bone Miner Res 2019;34(12):2213-9.

23) Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. New Engl J Med 2017;377(15):1417-27.

24) Cosman F, Crittenden DB, Ferrari S, et al. FRAME study:the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 2018;33(7):1219-26.

25) Tai TW, Li CC, Huang CF, et al. Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality:a nationwide population study. Bone 2022;154:116216. doi:10.1016/j.bone.2021.116216.

26) Tai TW, Hwang JS, Li CC,et al.The impact of various anti-osteoporosis drugs on all-cause mortality after hip fractures:a nationwide population study. J Bone Miner Res 2022;37(8):1520-6.